文献速递垂体与肾上腺疾病

荷兰21-羟化酶缺乏症二级检测试点研究

Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究评估了新生儿筛查中21-脱氧皮质醇(21-DF)二级检测与现行算法的准确性及周转时间。328份干血斑分析显示,将二级检测加入不确定的首次17-OHP结果可减少假阳性并避免所有第二次足跟采血,从而缩短转诊时间。

要点

  • 二级21-DF检测用于不确定的首次17-OHP结果,减少假阳性并避免第二次足跟采血。
  • 所有37例确诊经典CAH的新生儿21-DF均升高,33例假阳性及253/258例第二次采血阴性者21-DF均检测不到。
  • 将二级检测同时用于阳性和不确定的首次结果可消除所有假阳性,但延迟31例CAH患者转诊1-4天。

核心结论

  • 将二级21-DF检测应用于不确定的首次17-OHP结果,可减少假阳性、避免第二次足跟采血并缩短转诊时间。

研究设计与样本

  • 2017-2019年,荷兰地区新生儿筛查实验室将不确定和阳性首次17-OHP(免疫分析)的干血斑送至阿姆斯特丹UMC内分泌实验室,平行进行21-DF的LC-MS/MS检测,诊断经突变分析确认。

主要发现

  • 共分析328份干血斑,37例确诊经典CAH,33例假阳性,258例按现行算法在第二次足跟采血后判为阴性。
  • 二级检测中,所有37例确诊CAH的21-DF均升高,所有33例假阳性及253/258例第二次采血阴性者21-DF均检测不到。
  • 另5例新生儿21-DF升高,可能是筛查假阴性或二级检测假阳性。
  • 将二级结果加入不确定的首次结果,假阳性减至11例,并避免了全部286次第二次足跟采血。
  • 将二级检测同时用于阳性和不确定的首次结果,消除了所有假阳性,但延迟31例CAH患者转诊1-4天。

临床怎么用

  • 对首次17-OHP结果不确定的新生儿,可加做21-DF二级检测以减少假阳性并避免第二次足跟采血。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Newborn screening (NBS) for classic congenital adrenal hyperplasia (CAH) consists of 17-hydroxyprogesterone (17-OHP) measurement with gestational age-adjusted cutoffs. A second heel puncture (HP) is performed in newborns with inconclusive results to reduce false positives. OBJECTIVE: We assessed the accuracy and turnaround time of the current CAH NBS algorithm in comparison with alternative algorithms by performing a second-tier 21-deoxycortisol (21-DF) pilot study. METHODS: Dried blood spots (DBS) of newborns with inconclusive and positive 17-OHP (immunoassay) first HP results were sent from regional NBS laboratories to the Amsterdam UMC Endocrine Laboratory. In 2017-2019, 21-DF concentrations were analyzed by LC-MS/MS in parallel with routine NBS. Diagnoses were confirmed by mutation analysis. RESULTS: A total of 328 DBS were analyzed; 37 newborns had confirmed classic CAH, 33 were false-positive and 258 were categorized as negative in the second HP following the current algorithm. With second-tier testing, all 37 confirmed CAH had elevated 21-DF, while all 33 false positives and 253/258 second-HP negatives had undetectable 21-DF. The elevated 21-DF of the other 5 newborns may be NBS false negatives or second-tier false positives. Adding the second-tier results to inconclusive first HPs reduced the number of false positives to 11 and prevented all 286 second HPs. Adding the second tier to both positive and inconclusive first HPs eliminated all false positives but delayed referral for 31 CAH patients (1-4 days). CONCLUSION: Application of the second-tier 21-DF measurement to inconclusive first HPs improved our CAH NBS by reducing false positives, abolishing the second HP, and thereby shortening referral time.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Stroek K, Ruiter A, van der Linde A, et al. Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study. J Clin Endocrinol Metab. 2021. PMID: 34171085. doi:10.1210/clinem/dgab464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。